Enzymatica publ AB (ENZY) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.085x

Based on the latest financial reports, Enzymatica publ AB (ENZY) has a cash flow conversion efficiency ratio of -0.085x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-11.57 Million ≈ $-1.24 Million USD) by net assets (Skr135.68 Million ≈ $14.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ENZY defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Enzymatica publ AB - Cash Flow Conversion Efficiency Trend (2009–2024)

This chart illustrates how Enzymatica publ AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Enzymatica publ AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Enzymatica publ AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
577 Investment Corp VN:NBB	-0.139x
Dae Chang KO:012800	-0.035x
AB Science S.A PA:AB	0.149x
Uniflex Technology Inc TW:3321	0.050x
MHP Hotel AG XETRA:CDZ0	N/A
Catalyst Bancorp Inc NASDAQ:CLST	0.011x
Principal Real Estate Income Closed Fund NYSE:PGZ	0.029x
Amata VN PCL BK:AMATAV	0.029x

Annual Cash Flow Conversion Efficiency for Enzymatica publ AB (2009–2024)

The table below shows the annual cash flow conversion efficiency of Enzymatica publ AB from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Enzymatica publ AB worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr176.37 Million ≈ $18.98 Million	Skr-60.51 Million ≈ $-6.51 Million	-0.343x	+34.76%
2023-12-31	Skr76.61 Million ≈ $8.24 Million	Skr-40.29 Million ≈ $-4.34 Million	-0.526x	-2.86%
2022-12-31	Skr126.29 Million ≈ $13.59 Million	Skr-64.57 Million ≈ $-6.95 Million	-0.511x	-78.12%
2021-12-31	Skr124.97 Million ≈ $13.45 Million	Skr-35.87 Million ≈ $-3.86 Million	-0.287x	-187.36%
2020-12-31	Skr106.65 Million ≈ $11.48 Million	Skr-10.65 Million ≈ $-1.15 Million	-0.100x	+68.32%
2019-12-31	Skr119.20 Million ≈ $12.83 Million	Skr-37.58 Million ≈ $-4.04 Million	-0.315x	-74.80%
2018-12-31	Skr159.66 Million ≈ $17.18 Million	Skr-28.79 Million ≈ $-3.10 Million	-0.180x	+11.46%
2017-12-31	Skr110.70 Million ≈ $11.91 Million	Skr-22.55 Million ≈ $-2.43 Million	-0.204x	+24.73%
2016-12-31	Skr142.04 Million ≈ $15.29 Million	Skr-38.43 Million ≈ $-4.14 Million	-0.271x	+84.20%
2015-12-31	Skr21.98 Million ≈ $2.37 Million	Skr-37.65 Million ≈ $-4.05 Million	-1.712x	-162.87%
2014-12-31	Skr62.42 Million ≈ $6.72 Million	Skr-40.67 Million ≈ $-4.38 Million	-0.651x	+44.40%
2013-12-31	Skr15.73 Million ≈ $1.69 Million	Skr-18.43 Million ≈ $-1.98 Million	-1.172x	-127.13%
2012-12-31	Skr14.06 Million ≈ $1.51 Million	Skr-7.25 Million ≈ $-780.54K	-0.516x	+64.79%
2011-12-31	Skr3.31 Million ≈ $356.64K	Skr-4.86 Million ≈ $-522.58K	-1.465x	-1395.19%
2009-12-31	Skr-901.48K ≈ $-97.01K	Skr-101.99K ≈ $-10.98K	0.113x	--

About Enzymatica publ AB

ST:ENZY Sweden Drug Manufacturers - Specialty & Generic

Market Cap

$65.83 Million

Skr611.69 Million SEK

Market Cap Rank

#20905 Global

#378 in Sweden

Share Price

Skr2.52

Change (1 day)

+0.80%

52-Week Range

Skr1.65 - Skr3.20

All Time High

Skr770.83